Exhibit
99.1
|
NEWS
RELEASE
|
Lorus
Therapeutics Announces Settlement of
Secured
Convertible Debentures
TORONTO, CANADA - June 22,
2009 - Lorus Therapeutics Inc. (Lorus), a biopharmaceutical company
specializing in the research and development of pharmaceutical products and
technologies for the management of cancer, today reported that it has reached a
settlement with the debenture holders, The Erin Mills Investment Corporation
(TEMIC), with respect to the purchase and settlement of the $15 million secured
convertible debentures (the “Debentures”). Unless specified
otherwise, all amounts are in Canadian dollars.
Under
the agreement, Lorus has purchased all of the Debentures from TEMIC for a cash
payment of $3.3 million, the assignment of the rights under the license
agreement with ZOR Pharmaceuticals, LLC (ZOR) (described below), sale of
intellectual property associated with Virulizin and sale of Lorus’ shares in its
wholly owned subsidiary Pharma Immune Inc. which holds an equity interest in ZOR
(the “Consideration”). Under the agreement, Lorus will be entitled to
50% of any royalties received under the ZOR license agreement and 50% of the
deal value of any transaction completed in territories not covered by the ZOR
license agreement. Lorus also retains a perpetual, royalty free license for the
animal use of Virulizin. TEMIC will be fully responsible for all
clinical and regulatory costs associated with commercialization of Virulizin in
territories not covered by the ZOR license agreement. Lorus will assist TEMIC
with certain agreed upon services.
For receipt of this
Consideration TEMIC has released all security interest in the assets of
Lorus.
“The
settlement announced today is a key turning point for Lorus and our
shareholders”, said Dr. Aiping Young, President and CEO of Lorus, “We are now
able to focus on the development of our promising pipeline together with
establishing key partnerships and strategic alliances which have previously been
difficult to execute with the overhang of such a significant
liability. We are also pleased that this liability could be resolved
with no dilution to our shareholders while allowing us to retain a significant
portion of the future value of Virulizin.”
Agreement
with ZOR Pharmaceuticals
As
previously announced on April 8, 2008 Lorus entered into an exclusive
multinational license agreement with ZOR formed as a subsidiary of Zoticon
Bioventures Inc. Under the terms of the agreement, Lorus was entitled
to receive payments in excess of U.S.$12 million upon achievement of various
milestone events and royalties that vary from 10-20% depending on achieving of
sales of Virulizin® and subject to certain other adjustments. In addition, Lorus
received 25% of the initial equity in ZOR. ZOR is responsible for the
cost of all the clinical development, regulatory submissions and
commercialization of Virulizin® in North, South and Central America, Europe and
Israel (the “Territory”). Lorus had retained the rights in all other countries,
including Japan, Australia and New Zealand. Lorus shall pay to Zor an amount
equal to 10% of the amount of any royalty payments actually received by Lorus
from a third party from the sale of any product for animal use in the
Territory.
About
Lorus
Lorus is
a biopharmaceutical company focused on the research and development of novel
therapeutics in cancer. Lorus’ goal is to capitalize on its research,
preclinical, clinical and regulatory expertise by developing new drug candidates
that can be used, either alone, or in combination with other drugs, to
successfully manage cancer. Through its own discovery efforts and an
acquisition and in-licensing program, Lorus is building a portfolio of promising
anticancer drugs. Lorus Therapeutics Inc. is listed on the Toronto
Stock Exchange under the symbol LOR.
Forward
Looking Statements
This
press release contains forward-looking statements within the meaning of Canadian
and U.S. securities laws. Such statements include, but are not limited to,
statements relating to: financings and corporate reorganizations, the
establishment of corporate alliances, the Company’s plans, objectives,
expectations and intentions and other statements including words such as
“continue”, “expect”, “intend”, “will”, “should”, “would”, “may”, and other
similar expressions. Such statements reflect our current views with
respect to future events and are subject to risks and uncertainties and are
necessarily based upon a number of estimates and assumptions that, while
considered reasonable by us are inherently subject to significant business,
economic, competitive, political and social uncertainties and
contingencies. Many factors could cause our actual results,
performance or achievements to be materially different from any future results,
performance or achievements described in this press release. Such
expressed or implied forward looking statements could include, among
others: our ability to continue as a going concern, our ability to
obtain the capital required for research and operations; the inherent risks in
early stage drug development including demonstrating efficacy; development
time/cost and the regulatory approval process; the progress of our clinical
trials; our ability to find and enter into agreements with potential partners;
our ability to attract and retain key personnel; changing market conditions; and
other risks detailed from time-to-time in our ongoing filings with Canadian
securities regulators and the United States Securities and Exchange Commission
(the “SEC”).
Should
one or more of these risks or uncertainties materialize, or should the
assumptions set out in the section entitled “Risk Factors” in our filings with
Canadian securities regulators and the SEC underlying those forward-looking
statements prove incorrect, actual results may vary materially from those
described herein. These forward-looking statements are made as of the
date of this press release and we do not intend, and do not assume any
obligation, to update these forward-looking statements, except as required by
applicable law. We cannot assure you that such statements will prove
to be accurate as actual results and future events could differ materially from
those anticipated in such statements. Investors are cautioned that
forward-looking statements are not guarantees of future performance and
accordingly investors are cautioned not to put undue reliance on forward-looking
statements due to the inherent uncertainty therein.
Lorus
Therapeutics Inc.’s recent press releases are available through its website at
www.lorusthera.com. For Lorus' regulatory filings on SEDAR,
please go to www.sedar.com. For SEDAR filings prior to July 10, 2007
you can find these under the company profile for Global Summit Real Estate Inc.
(Old Lorus).
For
further information, please contact:
Lorus
Therapeutics Inc.
Dr.
Saeid Babaei, 1-416-798-1200 ext. 490
ir@lorusthera.com
2